-
Mycophenolate mofetil and its active metabolite mycophenolic acid, both used to prevent transplant rejection, are teratogenic and genotoxic. The available clinical evidence does not indicate an increased risk of malformation…
-
Letters were sent about Buccolam (midazolam), misoprostol vaginal delivery system (Mysodelle), noradrenaline, Relenza (zanamivir), mycophenolate mofetil/mycophenolic acid, Flolan, and Fludara.
-
Recombinant human erythropoietin (r-HuEPO) treatment has been associated with very rare cases of life-threatening severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and toxic epidermal necro…
-
Letters were sent about cladribine (Litak and Leustat), radium-223-dichloride (Xofigoâ–¼), and ERWINASE.
-
Alerts were recently issued about BD Alaris/Asena syringe pumps and Maxter Catheters nasogastric (NG) feeding tubes.
-
A European review has begun into the safety of radium-223 dichloride following an observed increase in the incidence of deaths and fractures in patients with chemotherapy-naive metastatic castration-resistant prostate cancer…
-
Some batches of gentamicin sulphate active pharmaceutical ingredient (API) used to manufacture gentamicin may contain higher than expected levels of histamine, which is a residual from the manufacturing process. Monitor pati…
-
Letters were sent in September about Dacogen (decitabine), Eperzanâ–¼(albiglutide), ERWINASE, ReoPro (abciximab), and recombinant human erythropoietins.
-
An alert was recently issued about Prismaflex haemofiltration machines.
-
Letters were sent about Arsenic Trioxide (Trisenox), Uptraviâ–¼ (selexipag), DepoCyte (cytarabine), Cinryzeâ–¼ (C1 esterase inhibitor [human]), and Clexane (enoxaparin sodium).
-
Denosumab is associated with a risk of osteonecrosis of the jaw, osteonecrosis of the external auditory canal has also been reported with denosumab.
-
A summary of letters sent to healthcare professionals, including an important reminder about the withdrawal of retigabine (Trobalt) from the market.
-
A summary of letters sent to relevant healthcare professionals.
-
Prescribing information has been updated to help to minimise the risk of serious adverse reactions in patients with cardiac disease.
-
Monitoring of blood electrolytes is essential in patients coprescribed a potassium-sparing diuretic and an angiotensin converting enzyme inhibitor (ACEi) or an angiotensin receptor blocker (ARB) for heart failure.
-
In light of feedback, we have clarified our article on concomitant use of these medicines in heart failure.
-
A summary of recent safety letters sent to relevant healthcare professionals
-
Mirabegron is now contraindicated in patients with severe uncontrolled hypertension; advice about regular monitoring is being introduced because of cases of severe hypertension.
-
A letter was sent to healthcare professionals about mirabegron for symptomatic treatment of urgency, increased
micturition frequency, or urgency incontinence.
-
A short course (3 to 7 days) may be used with caution in certain patients with an eGFR of 30 to 44 ml/min/1.73m2
-
Reports of reconstituted solution leaking from some models of extension sets and pumps.
-
There have been reports of thrombotic microangiopathy and nephrotic syndrome linked to interferon beta treatment.
-
New warnings due to risk of hyperkalaemia, hypotension, and impaired renal function have been agreed following an EU-wide review.
-
Evidence does not support any increased risk of cancer in patients who use these medicines.
-
Risk of aseptic peritonitis with Dianeal, Extraneal, and Nutrineal peritoneal dialysis solutions due to possible presence of endotoxin.
-
Prescribers should remain vigilant with regards to the similarity of these 2 drug names.
-
Patients should be advised to promptly report to their doctor any changes in their breast tissue such as lumps, pain, or nipple discharge.
-
You should take caution when you use NSAIDs in patients with renal impairment or are at risk.
-
Use of aliskiren can cause angioedema, a rare and serious side effect, and or acute renal failure.
-
The European Medicines Agency (EMA) has concluded that oral fluoroquinolone norfloxacin (Utinor) shouldn't be used to treat acute or chronic, complicated pyelonephritis.
-
Healthcare professionals are encouraged to report all suspected adverse reactions (ADRs) on the yellow card porftal to melt formulations of desmopressin.
-
Over-correction of haemoglobin concentration may increase the risk of death and serious cardiovascular events in patients with chronic kidney disease; it may increase the risk of thrombosis and related complications in patie…
-
To avoid the risk of air embolism, these products should not be infused under pressure.
-
Patients should be assessed regularly due to reported cases of suicidal ideation and suicidal behaviour during treatment with duloxetine or shortly after stopping treatment.
-
Cataract surgeons should check past or current use of α-1 adrenoreceptor antagonists for prostatic hypertrophy before surgery.
-
Patients who use products that contain maltose, xylose, or galactose should use glucose-specific monitors.